MedPath

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Phase 1
Completed
Conditions
Leukemia
Interventions
Registration Number
NCT01218477
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
33
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QDBMS-833923Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase) plus BMS-833923, 50 mg, QD
Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QDDasatinibParticipants received BMS-833923, 100 mg twice daily (BID) for 7 days then once daily (QD) + dasatinib, 100/140 mg QD, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QDBMS-833923Participants received BMS-833923, 200 mg twice daily (BID) for 7 days then 200 mg once daily (QD) plus dasatinib, 100 /140 mg QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Dasatinib, 100/140 mg QDDasatinibParticipants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QDDasatinibParticipants received BMS-833923, 200 mg twice daily (BID) for 7 days then 200 mg once daily (QD) plus dasatinib, 100 /140 mg QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QDDasatinibParticipants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase) plus BMS-833923, 50 mg, QD
Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QDBMS-833923Participants received BMS-833923, 100 mg twice daily (BID) for 7 days then once daily (QD) + dasatinib, 100/140 mg QD, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Primary Outcome Measures
NameTimeMethod
Recommended Phase 2 Dose (RP2D) of BMS-833923 Plus Dasatinib in Chronic Myeloid Leukemia-Chronic PhaseDay 1 to Week 80, with observation for DLT in Weeks 5-8

The following drug-related adverse events (AEs) occurring in the first 28 days of treatment were considered dose-limiting toxicities (DLT): Grade 4 hematologic AE lasting \>7 days; ≥Grade 3 nonhematologic AE, despite medical intervention; ≥Grade 2 AE uncontrolled by medical intervention and requiring treatment interruption for \>7 days. RP2D was that dose at which ≤1 of 6 patients had a DLT in the first 4 weeks of treatment. If \<3 patients were DLT-evaluable, up to 6 additional patients entered the same dose level. Accrual to a dose level closed if 6 patients were enrolled and \<3 were DLT-evaluable. If ≥3 patients at a dose level had no DLTs when a new patient enrolled, the dose was escalated to next level. If 1 DLT was observed in \<6 patients, ≥6 patients were required; if no additional DLT was observed, the dose was escalated to the next highest level. If ≥2 DLTs were observed in \<6 patients, that level exceeded the RP2D, and the dose was deescalated to the next lowest level.

Secondary Outcome Measures
NameTimeMethod
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting ToxicitiesDay 1 to Week 80, continuously, with observation for dose-limiting toxicities (DLTs) in Weeks 5-8

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment and may or may not be related to treatment. SAE=an untoward medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=having certain, probable, possible, or missing relationship to study drug. The following drug-related AEs occurring during the first 28 days of treatment with both agents were considered to be dose-limiting toxicities (DLTs): Grade 4 hematologic AE lasting \>7 days; ≥Grade 3 nonhematologic AE, despite adequate medical intervention; ≥Grade 2 AE not controlled by medical intervention and requiring treatment interruption for \>7 days.

Percentage of Participants With a Major Cytogenetic Response (MCyR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP)Day 1 to Week 80

Cytogenetic response (CyR) was based on the proportion of Philadelphia chromosome-positive (Ph+) cells in metaphase analysis of bone marrow. Complete cytogenetic response (CCyR)=0 Ph+ cells; Partial CyR (PCyR)=1 to 35 Ph+ cells; Minor CyCR= 36-65 Ph+ cells; Minimal CyCR= 66-95 Ph+ cells; No response= \>96 Ph+ cells. MCyR=CCyR + PCyR. Nilo=nilotinib; SOR=suboptimal response.

Percentage of Participants With a Major Hematologic Response (MHR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP)Day 1 to Week 80

MHR was defined as complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR for CML-Adv criteria: white blood cell count (WBC) ≤upper limit normal; absolute neutrophil count (ANC) ≥1,000/mm\^3; platelets ≥100,000/mm\^3; no blasts or promyelocytes in peripheral blood (PB); basophils \<5% in PB; myelocytes + metamyelocytes \< 5% in PB; no extramedullary involvement; blasts must be \<5%, if bone marrow assessment (BMA) performed. NEL had same criteria, but with lower thresholds for reconstitution of PB counts, as follows: Platelets ≥ 20,000/mm\^3 or ANC \>500/mm\^3. Confirmed MHR obtained if these criteria met and maintained for ≥28 days. CHR for CML-CP criteria WBC ≤10,000/mm\^3; platelets \<450,000/mm\^3; basophils \<5% in PB; no blasts or promyelocytes in PB; myelocytes + metamyelocytes \<5% in PB; no extramedullary involvement; blasts must be \<5% if BMA performed. Confirmed CHR obtained if these criteria met and maintained for ≥28 days. Nilo=nilotinib; SOR=suboptimal response.

Number of Participants With Grade 3-4 Abnormalities on Laboratory Test ResultsDay 1 to Week 80

ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal. Abnormalities were graded according to the Common Toxicity Criteria of the National Cancer Institute from 1 (least severe) to 4 (life threatening). ANC (\*10\^9): Grade 3, \<1.0- 0.5; Grade 4, \<0.5. Hemoglobin (mmol/L): Grade 3, \<4.9-4.0; Grade 4, \<4.0. Platelet count (\*10\^9/L): Grade 3, \<50.0-25.0; Grade 4, \<25. WBCs (\*10\^9): Grade 3, \<2.0-1.0; Grade 4, \<1.0. Hypocalcemia (mmol/L): Grade 3, \<1.75-1.5; Grade 4, \<1.5. Hyperkalemia (mmol/L): Grade 3, \>6.0-7.0; Grade 4, \>7.0. Hypokalemia (mmol/L): Grade 3, \<3.0-2.5; Grade 4, \<2.5. Hyponatremia (mmol/L), Grade 3, \<130-120; Grade 4, \<120. Hypermagnesemia (mg/dL): Grade 3, \>1.23-3.30; Grade 4, \>3.30. Phosphorus (mmol/L): Grade 3, \<0.6-0.3; Grade 4, \<0.3. Lipase (\*ULN): Grade 3, \>2.0-5.0; Grade 4, \>5.0.

Trial Locations

Locations (4)

University Of California Medical Center

🇺🇸

San Francisco, California, United States

Ut M.D. Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Local Institution

🇬🇧

Glasgow, United Kingdom

Sidney Kimmel Cancer Center At Johns Hopkins

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath